Pharmacoepidemiology and drug safety · 2026
Association Between Socioeconomic Conditions and Biologic Prescriptions for Inflammatory Bowel Diseases in the Brazilian Public Healthcare System: An Ecological Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Castro Caroline Tianeze, de Oliveira Luciane Cristina Feltrin, Santos Carlos Antonio de Souza Teles, Dos Santos Djanilson Barbosa
Аннотация
PURPOSE: Inflammatory bowel diseases (IBD) are chronic conditions affecting millions of people globally. Brazil's public healthcare system provides free access to IBD medications. However, socioeconomic conditions may affect prescribing patterns. This study examined associations between income inequality, human development, and biologic prescription rates for IBD in the Brazilian public health system (SUS).
METHODS: Data from the SUS Outpatient Information System (2008-2022) were analyzed. The biologic prescription rate (percentage of biologic prescriptions among all IBD prescriptions) was the outcome of interest. Random-effects negative binomial regression for panel data evaluated associations between the Gini Index, Municipal Human Development Index (MHDI), and biologic prescriptions while controlling for demographic, social, and healthcare variables.
RESULTS: Biologic prescription rates for IBD in Brazil increased from 3.03% to 16.69%. Municipalities with higher income inequality had 6% lower prescription rates than those with higher income equality (RR 0.94; 95% CI 0.92-0.96). Using low MHDI as the reference, municipalities with medium (RR 0.79; 95% CI 0.70-0.91), high (RR 0.68; 95% CI 0.60-0.78), and very high MHDI (RR 0.66; 95% CI 0.58-0.76) had progressively lower rates.
CONCLUSIONS: Income inequality and human development are associated with biologic prescription rates for IBD within the SUS. The paradoxical MHDI pattern probably reflects differential engagement of private health insurance across development levels, whereby biologic-eligible patients in wealthier municipalities access therapy outside the SUS and are not captured by SIA. These findings underscore the need for policies addressing structural disparities in IBD care and for future research integrating public and private sector prescription data.
METHODS: Data from the SUS Outpatient Information System (2008-2022) were analyzed. The biologic prescription rate (percentage of biologic prescriptions among all IBD prescriptions) was the outcome of interest. Random-effects negative binomial regression for panel data evaluated associations between the Gini Index, Municipal Human Development Index (MHDI), and biologic prescriptions while controlling for demographic, social, and healthcare variables.
RESULTS: Biologic prescription rates for IBD in Brazil increased from 3.03% to 16.69%. Municipalities with higher income inequality had 6% lower prescription rates than those with higher income equality (RR 0.94; 95% CI 0.92-0.96). Using low MHDI as the reference, municipalities with medium (RR 0.79; 95% CI 0.70-0.91), high (RR 0.68; 95% CI 0.60-0.78), and very high MHDI (RR 0.66; 95% CI 0.58-0.76) had progressively lower rates.
CONCLUSIONS: Income inequality and human development are associated with biologic prescription rates for IBD within the SUS. The paradoxical MHDI pattern probably reflects differential engagement of private health insurance across development levels, whereby biologic-eligible patients in wealthier municipalities access therapy outside the SUS and are not captured by SIA. These findings underscore the need for policies addressing structural disparities in IBD care and for future research integrating public and private sector prescription data.